

1 **Electronic Supplementary Information (ESI)**

2

3 **Chemical labeling achieves 8-oxo-7,8-dihydroguanine mapping in**
4 **microRNA transcriptome**

5 Changjiang Fan,^{* a,b} Xinyue Meng,^{a,b} Wei Yang,^{a,b} Peiyan Wang,^{a,b} Wenguang Chang,^a

6 Peifeng Li,^{* a} and Jianxun Wang^{* a,b}

7

8 ^a Institute for Translational Medicine, The Affiliated Hospital of Qingdao University,
9 Qingdao Medical College, Qingdao University, Qingdao 266021, Shandong, P. R.
10 China.

11 ^b School of Basic Medicine, Qingdao Medical College, Qingdao University, Qingdao
12 266071, Shandong, P. R. China.

13

14 Materials and Methods


15 Synthesis of N-(3-azidopropyl)-spermine-5-carboxamide (APSC)

16 The N-(3-azidopropyl)-spermine-5-carboxamide (APSC) was designed, and then
17 custom-synthesized in Chemily Glycoscience (Georgia, USA) that provided the
18 synthesis process as follows:

19 *Synthesis of Compound 1*

20 A solution of 3-amino-1-propanol (0.750 mL, 737 mg, 9.82 mmol) in tetrahydrofuran
21 (THF, 7 mL) was added with di-tert-butylidicarbonate (Boc₂O, 2.35 g, 10.8 mmol) and
22 then a solution of sodium carbonate (2.08 g, 19.6 mmol) in H₂O (5 mL). After
23 vigorously stirring for 2 h, the reaction mixture was poured over ethyl acetate (EtOAc).
24 The organic phase was washed with minimum amount of saturated sodium bicarbonate
25 (NaHCO₃) aqueous solution, separated, dried over MgSO₄, filtered and concentrated
26 under reduced pressure to provide a crude pale yellow oil (2 g, ~100%) that was used
27 without further purification.


28 This crude alcohol (1.05 g, 6 mmol) was dissolved in dichloromethane (CH₂Cl₂, DCM,
29 7 mL), and followed by adding 3 mL of KBr (722 mg, 6.07 mmol) aqueous solution and
30 2,2,6,6-tetramethylpiperidinoxy (TEMPO, 9 mg, 0.06 mmol), and the mixture was
31 cooled to 0 °C. After stirring for 10 min, a solution of NaOCl (492 mg, 6.61 mmol) and
32 NaHCO₃ (1.84 g, 21.9 mmol) in H₂O (9 mL) was added dropwise. After stirring for 1.5
33 h, additional NaOCl (104 mg, 1.4 mmol) was added, and thin-layer chromatography
34 (TLC) analysis indicated that the starting material was consumed within 20 min. The
35 product was extracted with DCM for two times. The combined organic phase was
36 separated, dried over anhydrous magnesium sulfate (MgSO₄), filtered and concentrated
37 under reduced pressure. The crude product was purified via column chromatography to
38 afford the desired compound 1 (792 mg, 76 %).



40 *Synthesis of Compound 2*

41 Thionyl chloride (2.24 g, 18.8 mmol) was added into a solution of N'-


42 benzyloxycarbonyl-L-ornithine (N'-Cbz-L-ornithine, 1.00 g, 3.76 mmol) in anhydrous
43 methanol (MeOH, 25 mL) at 0 °C. After completing the addition, the reaction mixture
44 was stirring for 18 hours at room temperature. The reaction system was then
45 concentrated under reduced pressure to obtain a yellowish solid. Recrystallization with
46 MeOH:ethyl acetate (EtOAc) (1:6) afforded the desired compound 2 as a white solid
47 (600 mg, 0.190 mmol). The filtrate and EtOAc washings were cooled for 48 h at -20°C
48 to provide additional product (177mg, 0.561 mmol). The two batches (total: 777 mg, 65
49 %) were combined for further use.



50

51 *Synthesis of Compound 3*

52 Compound 1 (988 mg, 5.7 mmol) was added into the solution of Compound 2 (1.6 g,
53 5.7 mmol) in anhydrous MeOH (30 mL). The reaction mixture was stirred for 10 min at
54 room temperature, followed by addition of NaBH₃CN (359 mg, 5.7 mmol). The reaction
55 was monitored by liquid chromatography mass spectrometry (LC-MS) until starting
56 material disappeared. The reaction was then quenched by saturated K₂CO₃ aqueous
57 solution and extracted with chloroform (CHCl₃). After removing solvent, the residue
58 was purified by the flash chromatography (EtOAc/Hexane 0 to 3/1) to afford pure
59 compound 3. Yield is always about 60%.




60

61

62 *Synthesis of Compound 4*


63 Compound 3 (1.618 g, 3.7 mmol) was dissolved in tetrahydrofuran (THF, 20 mL) and
64 saturated K₂CO₃ (766 mg in 10 mL water) was added. And then, Boc₂O (1.21 g, 5.55



85

86 *Synthesis of Compound 7*


87 Compound 6 (1.51 g, 2.88 mmol) was dissolved in EtOAc (20 mL) and Pd/C (150 mg,
 88 10% w/w) was added. The mixture was shaken at the atmosphere of H₂ (50 psi) and
 89 reaction was monitored by LC-MS. The mixture was filtered through celite. The filtrate
 90 was then concentrated to afford crude compound 7 which was used without further
 91 purification.



92

93 *Synthesis of Compound 8*

94 Compound 7 (1.286 g) was dissolved in anhydrous MeOH (30 mL). Compound 1 (498
 95 mg, 2.88 mmol) was then added. The reaction was then monitored by LC-MS until the
 96 starting material disappeared. The reaction was then quenched by saturated K₂CO₃ and
 97 extracted with CHCl₃. The solvent was then removed and the residue was used in the
 98 next step without further purification.




99

100 *Synthesis of Compound 9*

101 Compound 8 (1.74 g) was dissolved in THF (20 mL) and saturated K₂CO₃ (597 mg in


102 5 mL water) was added. Then Boc_2O (942 mg, 4.32 mmol) was added. The reaction was
 103 monitored by LC-MS. The reaction system was diluted with EtOAc and the organic
 104 layers were combined and washed with saturated NaHCO_3 . The solvent was
 105 concentrated under reduced pressure. The residue was purified by the flash
 106 chromatography (EtOAc/Hexane 0 to 1/1) to afford the pure compound 9 (751 mg,
 107 1.067 mmol).



108

109 *Synthesis of Compound 10*

110 Compound 9 (751 mg, 1.067 mmol) was dissolved in anhydrous DCM (15 mL) and the
 111 solution was cooled to 0 °C. Triethylamine (NEt_3 , 0.22 mL, 1.6 mmol) was added and
 112 followed by the slow addition of methanesulfonyl chloride (MsCl , 90 μL , 1.05 mmol).
 113 The reaction was then stirred at 0 °C for 1 hour when TLC indicated that all the starting
 114 material disappeared. The reaction was quenched by brine and extracted by CHCl_3 . The
 115 combined organic layers was evaporated under reduced pressure. The residue was used
 116 in the next step without further purification.




117

118 *Synthesis of Compound 11*

119 Compound 10 (835 mg, 1.067 mmol) was dissolved in anhydrous DMF (15 mL). NaN_3
 120 (104 mg, 1.6 mmol) was added and the reaction was heated to 70 °C. After the reaction
 121 was complete indicated with LC-MS, the reaction system was cooled down to room
 122 temperature. Brine was added and the mixture was extracted by methyl tert-butyl ether.
 123 The solvent was then removed under reduced pressure and the residue was then


124 subjected to flash chromatography to afford pure compound 11 (450 mg, 0.617 mmol).



125

126 *Synthesis of APSC hydrochloride*

127 Compound 11 (450 mg, 0.617 mmol) was dissolved in a solution of 4M HCl in dioxane
128 (10 mL) and stirred overnight. The reaction mixture was subjected to ultrasonic
129 treatment for 2 hours, during which a lot of light yellow precipitate formed. The solvent
130 was removed and the solid was collected to afford light yellow solid (292 mg), namely
131 APSC hydrochloride.



132

133 **8-oxoGua labeling with APSC**

134 The 10-nt DNA or RNA templates with or without an 8-oxoGua (15 μ M) was incubated
135 with APSC (0.3 mM) in 18 μ L of sodium phosphate buffer (SPB, 20 mM, pH 7.5), and
136 2 μ L of $K_3Fe(CN)_6$ (6 mM) or Na_2IrCl_6 (1 mM) was added.^{1,2} After gentle mixing with
137 a pipette, the reaction was carried out for 30 min at 25 $^{\circ}$ C and then quenched by adding
138 5 μ L of EDTA solution (20 mM, pH 8.0). The DNA/RNA was precipitated in 1.5
139 volumes of 100% isopropanol after adding 2 μ L of glycogen (10 mg/mL, Thermo) at -
140 20 $^{\circ}$ C overnight. The DNA/RNA pellet was obtained through centrifuging for 10 min
141 at 12000 rpm at 4 $^{\circ}$ C and washed with 80% ethanol, which was dissolved in deionized
142 water.

143 Considering the fact that APSC has two primary amine groups, two different isomers
144 of adducts may be formed during the oxidation/addition step. However, no matter
145 which adduct isomer form is formed, it will not affect the subsequent pull-down of 8-
146 oxoGua-containing nucleic acids.

147 The 10-nt DNA used in this experiment is presented below:

148 5'-CAGTAXTGAC-3' X = 8-oxoGua

149 The 10-nt RNA used in this experiment is presented below:

150 5'-CAGUAXCGAC-3' X = 8-oxoGua

151 **The reactions of APSC with synthetic DNA containing 8-BrGua, 8-oxoAde, or 5-**
152 **fCyt and RNA containing 8-oxoGua**

153 The 10-mer DNAs (15 μ M) containing an 8-BrGua, 8-oxoAde, or 5-fCyt and 21-nt
154 RNA containing an 8-oxoGua were reacted with $K_3Fe(CN)_6$ (0.6 mM) in the presence
155 of APSC (0.3 mM) in 20 μ L of SPB (20 mM, pH 7.5) treated with diethyl pyrocarbonate
156 (DEPC) (named as RNase-free SPB), respectively. After incubation for 30 min at 25
157 $^{\circ}C$, the reaction was quenched with EDTA (1mM, pH 8). The DNA was precipitated in
158 isopropanol and washed with 80% ethanol. They were dissolved in 10 μ L of RNase-
159 free water DNA.

160 The 10-mer DNA templates (Takara) used in this experiment are presented below:

161 5'-CAGTAXTGAC-3' X = dG

162 5'-CAGTAYTGAC-3' Y = 8-BrGua

163 5'-GTACGACXTG-3' X = 8-oxoAde

164 5'-GTACGAYATG-3' Y = 5-fCyt

165 The 21-nt RNA template (Takara) used in this study is presented below.

166 5'-CGAUAUCGUAUCXCGUAUCGC-3' X = 8-oxoGua

167 **Cell Culture**

168 4T1 breast carcinoma cells were obtained from Dr. Peipei Shan, and cultured in the
169 RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum
170 (FBS, Biological Industries), 100 μ M nonessential amino acids, 100 μ M sodium
171 pyruvate, 100 μ g/ml streptomycin-100 unit/ml penicillin in a 5% CO₂ incubator at 37
172 °C.

173 Human aortic vascular smooth muscle cells (VSMCs) were originally purchased from
174 ATCC. They were cultured in the Dulbecco's Modified Eagle's Medium (DMEM,
175 Gibco) supplemented with 10% FBS, and 100 units/mL penicillin-100 μ g/mL
176 streptomycin (Hyclone) at 37 °C, 5% CO₂ atmosphere. Cells were passed at 70-80% of
177 confluency by using the solution of trypsin (0.25%)-EDTA (0.02%) in DMEM. For
178 H₂O₂ treatment, the VSMCs were cultured in the medium supplemented with 100 μ M
179 H₂O₂ for 12 h.³

180 **Preparation of cellular DNA and small RNAs**

181 Genomic DNA was extracted from VSMCs by using genomic DNA extraction kits
182 (Tiangen Biotech, Beijing, China), in which 2-mercaptoethanol (100 mM) was
183 supplemented in the solutions. VSMC genomic DNA and rat genomic DNA (obtained
184 from Dr. Tao Xu) was dissolved in 50 μ L of Tris-HCl buffer (10 mM, pH 8.0),
185 respectively, and the concentration was determined with a Nanodrop (Thermo Fisher
186 Scientific).

187 50 µg of genomic DNA was diluted with 100 µL of Tris-HCl buffer (10 mM, pH 8.0)
188 and then sonicated into 150-300 bp with a focused-ultrasonicator (M220, Covaris). To
189 inhibit adventitious formation of 8-oxoGua, the antioxidant, 2-mercaptoethanol (100
190 mM), was used in the steps for DNA extraction and fragmentation by sonication. The
191 fragmented DNA was precipitated with isopropanol in the presence of glycogen at -20
192 °C overnight. After centrifugation, the DNA pellet was washed twice with 80% ethanol,
193 and dissolved in 40 µL of SPB (20 mM, pH 7.5).

194 The small RNAs (< 200 bp in length) were extracted from the VSMCs and 4T1 cells
195 (obtained from Dr. Peipei Shan) with miRNA isolation kit (DP501, Tiangen Biotech),
196 in which 2-mercaptoethanol (100 mM) was supplemented in solutions, respectively.
197 They were recovered and purified with twice ethanol precipitation in the presence of
198 glycogen. The RNA pellet was re-suspended in 50 µL of the RNase-free SPB (20 mM,
199 pH 7.5); its concentration was measured by using the Nanodrop, and about 40 µg for
200 each group was obtained.

201 **8-oxoGua labeling and pull-down enrichment**

202 8-oxoGua tagging with APSC was carried out as described above. Synthetic DNA
203 template (1 nmol) was reacted with APSC (0.3 mM) and $K_3Fe(CN)_6$ (0.6 mM) in 50
204 µL of reaction mixture. For genomic DNA, 40 µg of the DNA fragments (150-300 bp)
205 was also labeled in the 50 µL of SPB (20 mM, pH 7.5) containing 0.3 mM of APSC
206 and 0.6 mM of $K_3Fe(CN)_6$. For small RNA, the 8-oxoGua labeling was carried out in
207 50 µL of RNase-free SPB (20 mM, pH 7.5) containing 20 µg of RNAs, 0.3 mM of
208 APSC, and 0.6 mM of $K_3Fe(CN)_6$. All the reactions were carried out for 30 min at 25

209 °C, and NA samples were then precipitated with isopropanol in the presence of
210 glycogen at -20°C overnight, respectively.

211 The resultant 8-oxoGua-N₃ was purified via twice precipitation with isopropanol in the
212 presence of glycogen, and then dissolved in 40 uL of 10 mM Tris-HCl buffer (pH 7.4),
213 respectively. The click chemistry was carried out by adding the biotin-terminated
214 functional linker with disulfide and DBCO (200 μM) and followed by incubating at 37
215 °C for 3 hours at 800 rpm in the Eppendorf thermomixer.⁴ The sample was purified by
216 twice isopropanol precipitation and washing with 80% ethanol.

217 The pull-down of biotinylated NAs (namely 8-oxoGua-N₃-S-S-Biotin) was carried out
218 with the streptavidin-coated magnetic beads (65001, Invitrogen) according to
219 manufacturer's instructions with minor modifications. Tween-20 was added into the
220 washing and binding buffer at final concentration of 0.01% and 0.02% (v/v),
221 respectively. 40 μL of magnetic bead suspension was used for binding of 8-oxoGua-
222 N₃-S-S-Biotin in each sample. After washing the beads at least six times, 50 μL of
223 dithiothreitol (DTT) solution (60 mM) in RNase-free water was employed to release
224 8-oxoGua-containing NA fragments (namely 8-oxoGua-N₃-SH) by incubating at 25 °C
225 for 1 h under vortexing at 1200 rpm. The solution of 8-oxoGua-N₃-SH was collected
226 after separating the magnetic beads with a magnet, recovered via isopropanol
227 precipitation, and then dissolved in 20 μL of RNase-free water.

228 A 12-mer DNA template (Takara) used in this experiment is presented below:

229 5'-CCGXAATTGGCC-3' X = 8-oxoGua

230 **Amplification assay of DNA containing 8-oxoGua-N₃-SH using polymerase chain**
231 **reaction (PCR)**

232 The 100-mer single-stranded DNA (100 ng) containing an 8-oxoGua was subjected to
233 8-oxoGua pull-down protocol. The enriched 8-oxoGua-N₃-SH was acted as the
234 template to perform PCR using various commercial DNA polymerases, including Deep
235 Vent® (exo-) DNA Polymerase (NEB), TruePrep Amplify Enzyme (Vazyme), Pfu
236 DNA Polymerase (Promega), Q5® High-Fidelity DNA Polymerases (NEB), according
237 to the manufacturer's instructions, respectively. Besides, as the control, the 8-oxoGua
238 pull-down protocol was also carried out on the model DNA except APSC tagging,
239 followed by PCR with Deep Vent® (exo-) DNA Polymerase (NEB). Reaction mixtures
240 were incubated at 95 °C for 5 minutes, followed by 30 cycles of 15 s at 95 °C, 30 s at
241 55 °C, and 15 s at 72 °C. The PCR products were analyzed by electrophoresis on 1.5%
242 agarose gels and imaged under UV light after staining with 1×Ultra GelRed Nucleic
243 Acid Stain (Vazyme). The 100 bp DNA Ladder (Vazyme) was used as a size marker.
244 The 100-mer single-stranded DNA (Takara) used in this study is presented below:

245 5'-

246 CCTCACCATCTCAACCAATATTATATTACGCGTATATCGCGTATAACXCGTA

247 TATCGCGTATCGCGTATTTTCGCGTTATAATATTGAGGGAGAAGTGGTGA-3'

248 X = 8-oxoGua or G

249 The sequences of PCR primers (Sangon Biotech Co., Ltd, Shanghai, China) were as
250 follows:

251 Forward primer: 5'-CCTCACCATCTCAACCAATA-3'

252 Reverse primer: 5'-TCACCACTTCTCCCTCAATA-3'

253 **Fluorescence labeling of 8-oxoGua**

254 As described above, synthetic 35-bp synthetic DNA and 21-nt RNA templates with or
255 without 8-oxoGua (1 nmol), VSMC DNA (5 µg), and VSMC RNA (5 µg) was reacted
256 with APSC (0.3 mM) in 50 µL of SPB (20 mM, pH 7.5) in the presence of $K_3Fe(CN)_6$
257 (0.6 mM), respectively. The resultant 8-oxoGua- N_3 was obtained by isopropanol
258 precipitation, and then dissolved in 40 µL of 10 mM Tris-HCl buffer (pH 7.4)
259 containing FITC-DBCO (200 µM). The reaction was carried out at 37 °C for 3 hours,
260 and purified by twice precipitation in isopropanol. The FITC-labeled samples were
261 dissolved in 10 mM Tris-HCl buffer (pH 7.4).

262 The 35-bp DNA template (Takara) used in this study is presented below (The
263 complementary strand is not listed):

264 5'-AATTCGAGCTGGCGCGXACGTATGAGGAGCGGTAC-3' X = 8-oxoGua

265 **Quantification of 8-oxoGua by fluorescence assay**

266 DNA content was determined using a Nanodrop. The fluorescence intensity of FITC-
267 labeled sample was measured, respectively, at an excitation wavelength of 495 nm and
268 emission wavelength of 525 nm in a 96-well plate with 50 µL of solution per well using
269 a micro-plate reader. For the 35-bp DNA templates, the graph was plotted with the
270 fluorescence intensity versus corresponding 8-oxoGua concentration, which was also
271 served as standard curve. The 8-oxoGua content of VSMC DNA (100 ng) after adding
272 DNA templates, including 52 nM, 104 nM, or 156 nM, was also determined. In

273 addition, the fluorescence intensity was measured for calculation of 8-oxoGua content
274 in DNA and RNA of the VSMCs treated with or without H₂O₂, respectively.

275 **Dot-blot assays**

276 The synthetic DNA templates with or without 8-oxoGua, cellular DNAs and RNAs
277 were labeled with FITC, and purified, respectively. Each of them (60 ng/μL) was
278 spotted on a positively charged nylon membrane (INYC00010, Millipore). They were
279 observed under a fluorescence imaging system (Tanon, 5200 Multi).

280 **Spike-in study and qPCR validation of 8-oxoGua enrichment**

281 The spike-in and qPCR experiments were used to validate the specificity and efficiency
282 of the protocol for labeling and pull-down of 8-oxoGua-containing NAs. 100 pg of
283 synthetic 100-bp DNA template (Takara) with or without an 8-oxoGua was spiked into
284 the 5 μg of rat genomic DNA fragments, respectively, followed by 8-oxoGua labeling
285 and enrichment. In addition, the enrichment protocol was also performed on 4T1 cell-
286 derived small RNAs (5 μg) spiked with synthetic 21-nt RNA containing an 8-oxoGua
287 (2 ng).

288 All qPCR reactions were performed in triplicate using a CFX96 Real-Time PCR
289 System (Bio-Rad). For DNA, 2 ng of the input (genomic DNA fragments spiked with
290 model DNA) or pull-down DNA was used in a 20 μL of qPCR reaction containing 1×
291 IQ SYBR Green Supermix (Bio RAD), forward primer (0.5 μM), and reverse primer
292 (0.5 μM). Reaction mixtures were incubated at 95 °C for 5 minutes, followed by 40
293 cycles of 15 s at 95 °C, 30 s at 55 °C, and 15 s at 72 °C.

294 The 100-bp DNA template (Takara) containing an 8-oxoGua used in this study is
295 presented below (The complementary strand is not listed):

296 5'-

297 CCTCACCATCTCAACCAATATTATATTACGCGTATATCGCGTATACXCGTA

298 TATCGCGTATCGCGTATTTTCGCGTTATAATATTGAGGGAGAAGTGGTGA-3'

299 X = 8-oxoGua

300 The sequences of primers (Sangon Biotech Co., Ltd, Shanghai, China) were as follows:

301 Forward primer: 5'-CCTCACCATCTCAACCAATA-3'

302 Reverse primer: 5'-TCACCACTTCTCCCTCAATA-3'

303 For small RNA, cDNA was synthesized from the small RNAs (extracted from 4T1
304 cells) spiked with model RNA (input) and enriched RNAs, respectively, using the 21-
305 nt RNA-specific stem-loop primer (Sangon Biotech Co., Ltd, Shanghai). Typically, 50
306 ng of RNA sample was respectively reverse-transcribed into cDNA in a 20 μ L of
307 reaction mixture containing 100 nM stem-loop primer, 1 \times PrimeScript Buffer 2
308 (Takara), and 1 μ L PrimeScript RT Enzyme Mix I (Takara) using a T10 thermal cycler
309 (Bio-Rad) at 37 $^{\circ}$ C for 15 min, 85 $^{\circ}$ C for 15 sec, and 4 $^{\circ}$ C for 5 min. The cDNA solution
310 was diluted to a final volume of 100 μ L. 2 μ L of diluted cDNA was used in each 20 μ L
311 of qPCR reaction containing 1 \times IQ SYBR Green Supermix (Bio RAD), forward primer
312 (0.5 μ M), and reverse primer (0.5 μ M). Reaction was run with an initial denaturation at
313 20 $^{\circ}$ C for 5 min, followed by 40 cycles of 15 s at 95 $^{\circ}$ C, 30 s at 55 $^{\circ}$ C, and 15 s at 72
314 $^{\circ}$ C. The sequences of primers (Sangon Biotech Co., Ltd, Shanghai) were as follows:

315 Stem-loop primer: 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTTCGCACTGG-

316 ATACGACGCGATAC-3'

317 Forward primer: 5'-GCAGGGTCCGAGGTATTC-3'

318 Reverse primer: 5'-CGATATCGTATCGCGTATCG-3'

319 Fold enrichment was calculated as 2^{-dC_t} , where $dC_t = C_t(\text{enriched}) - C_t(\text{Input})$.

320 **Synthesis of DNA containing 5-hydroxycytosine (5-OHCyt) and RNA containing**
321 **5-hydroxyuracil (5-OHUra)**

322 The 5-OHCyt-containing DNA is synthesized by PCR amplification using a modified
323 deoxyribonucleoside triphosphate (dNTP), namely 5-hydroxy-2'-deoxycytidine-5'-
324 triphosphate (5-hydroxy-dCTP, B8102, APEX BIO), and three conventional dNTP, i.e.
325 2'-deoxyadenosine-5'-triphosphate (dATP), 2'-deoxyguanosine-5'-triphosphate
326 (dGTP), and 2'-deoxythymidine-5'-triphosphate (dTTP). The plasmid containing Mfn2
327 gene and Hieff[®] Taq DNA Polymerase (Yeasen, China) was used as the PCR template
328 and DNA polymerase, respectively. The primers for synthesis of 5-OHCyt-containing
329 DNA were listed below. The PCR product was purified with DNA clean beads (N411,
330 Vazyme Biotech Co. Ltd, China), and examined by agarose gel. Besides, the control
331 DNA template is synthesized with the same primer and conventional dNTPs, including
332 dATP, dTTP, dCTP, and dGTP.

333 For preparation of the 5-OHUra-containing RNA, the DNA template containing T7
334 promoter at the 5'-end is first synthesized by using the plasmid containing Mfn2 gene
335 as the template. The primers for synthesis of the DNA containing T7 promoter were
336 listed below. The 5-OHUra-containing RNA is synthesized using T7 high yield RNA

337 transcription kit (TR101, Vazyme Biotech Co. Ltd, China) after replacing uridine-5'-
338 triphosphate (UTP) with 5-hydroxy-UTP (B8060, APEXBIO), purified with RNA clean
339 beads (N412, Vazyme Biotech Co. Ltd, China), and examined by agarose gel. Besides,
340 the control RNA template is synthesized with conventional NTPs, namely ATP, TTP,
341 CTP, and GTP.

342 Primers for synthesis of 5-OHCyt-containing DNA:

343 Forward primer: 5'-CAAGGTCAGGGGAATCAGCG-3'

344 Reverse primer: 5'-GCTAGCTGGTTCACGGTCTT-3'

345 Primers for synthesis of the DNA containing T7 promoter:

346 Forward primer: 5'-TAATACGACTCACTATAGGGCAAGGTCAGGGGAATCAG-
347 CG-3'

348 Reverse primer: 5'-GCTAGCTGGTTCACGGTCTT-3'

349 **Pull-down yield assay**

350 8-oxoGua labeling and enrichment were carried out on synthetic model DNA and RNA
351 for assessing their enrichment yields, respectively. 1 μg of the 100-bp DNA or 21-nt
352 RNA containing an 8-oxoGua was treated with 8-oxoGua labeling, and then pulled
353 down by using 50 μL of streptavidin magnetic beads (65001, Invitrogen), respectively.
354 The DNA or RNA was recovered via isopropanol precipitation, followed by washing
355 with 80% ethanol. After dissolving in 20 μL of RNase-free water, their concentrations
356 were measured with a Nanodrop. 721.3 ± 81.0 ng of DNA-8-oxoGua and 757.3 ± 110.2
357 ng of RNA-8-oxoGua was harvested. As expected, almost no DNA and RNA without
358 8-oxoGua modification was collected. In addition, the same labeling and pull-down

359 protocol was also performed on 4 μg of 5-OHUrA-containing RNA and 5-OHCyt-
360 containing DNA, respectively. $0.014 \pm 0.003 \mu\text{g}$ of RNA (without 5-OHUrA), $0.137 \pm$
361 $0.019 \mu\text{g}$ of RNA-5-OHUrA, $0.011 \pm 0.004 \mu\text{g}$ of DNA (without 5-OHCyt), and 0.048
362 $\pm 0.004 \mu\text{g}$ of DNA-5-OHCyt was obtained.

363 **Native polyacrylamide gel electrophoresis (PAGE)**

364 Samples were suspended in 1 \times DNA loading buffer and then loaded onto a 20%
365 polyacrylamide gel (19:1) (Solarbio, Beijing, China). After electrophoresis, the gel was
366 stained with SYBR Gold (Invitrogen) and visualized under UV light.

367 **Electrospray ionization-ion trap mass spectrometry (ESI-ITMS) analysis**

368 DNA and RNA samples were analyzed by electrospray ionization ion trap mass
369 spectrometry (ESI-ITMS) in negative ion mode. The sample was dissolved in water and
370 the final concentration is 2-5 μM , and which was infused into the mass spectrometer
371 (LCQ Deca XP, Thermo Finnigan) at a flow rate of 10 $\mu\text{L}/\text{min}$. The source and
372 desolvation temperatures were 110 $^{\circ}\text{C}$ and 350 $^{\circ}\text{C}$ respectively. Capillary voltage and
373 cone voltage was set to 4.5 kV and 46 V, respectively. The data was processed by using
374 the ProMass deconvolution software (Thermo Fisher Scientific).

375 **Library preparation and deep sequencing**

376 The 8-oxoGua enrichment described above as well as subsequent sequencing was
377 termed as APSC-8-oxoGua-seq. For DNA sample, 50 ng of DNA fragments or pull-
378 down 8-oxoGua-containing DNA fragments were used to prepare DNA sequencing-
379 library with NEBNext Ultra II DNA Library Preparation Kit for Illumina (E7645, NEB)
380 and NEBNext Multiplex Oligos for Illumina (E7600, NEB) according to

381 manufacturer's instructions. After adaptor ligation, cleanup of adaptor-ligated DNA
382 was performed to remove adaptor contamination using 1.1 volumes of AMPure XP
383 Beads. DNA library fragments of 200-400 bp were size selected with AMPure XP
384 Beads after PCR amplification. The purified DNA libraries were paired-end sequenced
385 on the Illumina NovaSeq platform (Berry Genomics, Beijing, China).

386 For small RNA, 40 ng of small RNAs (input) or pull-down 8-oxoGua-containing small
387 RNAs was employed as starting material to construct small RNA sequencing-library
388 by using VAHTS Small RNA Library Prep Kit for Illumina (NR801, Vazyme Biotech)
389 and VAHTS Small RNA Index Primer Kit for Illumina (N813, Vazyme Biotech)
390 following manufacturer's instructions. They were ligated with RNA 3' and 5' adapters,
391 and then the reverse transcription was performed with the primer to the 3' adapter. After
392 PCR amplification, the products were purified gel electrophoresis, and then sequenced
393 on an Illumina HiSeq 2500 (LC-Sciences, Hangzhou, China).

394 **G>T transversion test**

395 To evaluate G>T transversion at 8-oxoGua sites after the pull-down protocol and PCR,
396 a 100-bp synthetic DNA template containing two 8-oxoGua was subjected to APSC-
397 based 8-oxoGua labeling, enrichment, and sequencing (namely APSC-8-oxoGua-seq).
398 This 100-bp synthetic DNA template (Takara) containing two 8-oxoGua is presented
399 below (The complementary strand is not listed):

400 5'-

401 CCGCTCGAGATCGATCGATCGATCGATCGAATCXATCGATCGATCGATCG

402 ATCATCGTAGCATCXACATGATCGATCGAATCGATCGATCGAGGTACCCA-

403 3' X = 8-oxoGua

404 **Bioinformatics analysis**

405 For DNA sequencing data, the raw FASTQ data were trimmed by using Trim_Galore
406 (version 0.6.6, parameters: --phred33 --length 36 --stringency 5 --paired) and were
407 aligned to human reference genome, hg38, by using bowtie2 (version 2.3.5.1). Peak
408 calling was performed using MACS2 (version 2.1.0) with the input sample as control
409 ($p < 0.01$, fold-enrichment > 3). Peak annotation was performed using HOMER.

410 For small RNA data, the raw sequencing reads were subjected to the ACGT101-miR
411 program (LC Sciences, Houston, Texas, USA). The resultant unique sequences with
412 length of 18-26 nt were aligned to precursors/mature miRNA in miRBase 22.0 to
413 identify known miRNAs. The unmapped sequences were aligned to genome sequence
414 of human (*Homo sapiens*, Ensembl_v96) and the hairpin RNA structures containing
415 sequences were predicted with the RNAfold software to identify potentially novel
416 miRNAs. Total miRNA read counts were normalized and the relative expression was
417 calculated. The differential expression was analyzed by using Fisher exact test and Chi-
418 squared 2×2 test, where $p < 0.001$ was considered statistically significant.

419 G>T transversion was analyzed with an in-house Python script containing Bowtie. For
420 model DNA template, random $30 \times$ reads were selected for drawing the heatmap
421 graphics using $\log_{10}(\text{reads number})$. For cellular miRNA, the target genes were
422 predicted using online TargetScan and miRanda databases on the wild-type sequence
423 and the sequences after the substitution of 8-oxoGua with U at 8-oxoGua sites,


424 respectively. The differential target genes were analyzed using the OmicStudio tools
425 (<https://www.omicstudio.cn/tool>) for Gene Ontology (GO) analysis as well as Kyoto
426 Encyclopedia of Genes and Genomes (KEGG) pathway analysis.

427 **Statistical analysis**

428 The results were expressed as means \pm standard deviation (SD) with at least three
429 parallel samples. The results of two groups were statistically analyzed with Student's
430 t-test, and a significant difference was defined as $p < 0.05$ unless stated otherwise.

431 **Data availability**


432 Sequencing data of this study have been deposited into the National Center for
433 Biotechnology Information (NCBI) under accession number PRJNA692633.



434

435 **Fig. S1.** NMR and mass spectroscopy characterization of APSC. (A) ^1H NMR
 436 spectrum, (B) ^{13}C NMR spectrum, (C) mass spectrum.


437



438


439 **Fig. S2.** Native polyacrylamide gel electrophoresis (PAGE) analysis for APSC adduct
 440 formation with 8-oxoGua-containing 10-mer DNA (A) and 21-nt RNA (B) as well as
 441 for enrichment process of 8-oxoGua-containing 12-mer DNA. (A) Lane a: 10-mer DNA
 442 containing an 8-oxoGua, Lane b: 10-mer DNA containing an 8-oxoGua with APSC and
 443 $K_3Fe(CN)_6$. (B) Lane a: 21-nt RNA containing an 8-oxoGua, Lane b: 21-nt RNA
 444 containing an 8-oxoGua with APSC and $K_3Fe(CN)_6$. (C) Lane a: 12-mer DNA
 445 containing an 8-oxoGua, Lane b: 12-mer DNA-8-oxoGua- N_3 , Lane c: 12-mer DNA-8-
 446 oxoGua-SH. The crude reaction mixtures are directly analysed by PAGE.

447



448


449 **Fig. S3.** The formation of APSC adduct in a 10-mer DNA containing an 8-oxoGua at
 450 the presence of $K_3Fe(CN)_6$ or Na_2IrCl_6 in sodium phosphate buffer (SPB, 20 mM, pH
 451 7.5), respectively. The higher reaction efficiency was observed under oxidation with
 452 $K_3Fe(CN)_6$.



453

454 **Fig. S4.** The formation of APSC adduct in a 10-mer RNA containing an 8-oxoGua at
 455 the presence of $\text{K}_3\text{Fe}(\text{CN})_6$ or Na_2IrCl_6 in SPB (20 mM, pH 7.5), respectively. The same
 456 high reaction efficiency (almost 100%) was observed under both conditions.


457



459

460 **Fig. S5.** PAGE analysis for the reaction between APSC and 10-mer DNA containing
 461 8-BrGua, 8-oxoAde or 5-fCyt, respectively, upon oxidation with $K_3Fe(CN)_6$. Lane a:
 462 8-BrGua, Lane b: 8-BrGua with APSC, Lane c: 8-oxoAde, Lane d: 8-oxoAde with
 463 APSC, Lane e: 5-fCyt, Lane f: 5-fCyt with APSC. No APSC adducts were formed
 464 in these reactions.


465



466


467 **Fig. S6.** Electrospray ionization-ion trap mass spectrometry (ESI-ITMS) analysis for
 468 the reaction between APSC and 10-mer DNA containing 8-BrGua, 8-oxoAde or 5-fCyt,
 469 respectively. No APSC adducts were detected.

470



471


472 **Fig. S7.** Efficient labeling of 8-oxoGua in DNA and RNA, respectively, with APSC
 473 and subsequent DBCO-FITC. Fluorescence intensity of FITC-labeled (A) DNA and
 474 (B) RNA containing an 8-oxoGua is linearly related to DNA and RNA concentration,
 475 respectively. (C) Determination of the increased concentration of 8-oxoGua-containing
 476 DNA added into gDNA solution. The measured increase of 8-oxoGua concentration
 477 (indicated with arrow) is in agreement with actual increase of 8-oxoGua concentration.
 478 (D) Dot-blot assay of DNA or RNA templates labeled with APSC and DBCO-FITC.
 479 Row G: The template without 8-oxoGua. Row 8-oxoGua: The template with an 8-
 480 oxoGua. Lane control: The starting materials. Lane labeling: FITC-labeled samples. (E)
 481 Dot-blot assay of gDNA and total RNA extracted from the VSMCs treated with or
 482 without (w/o) H₂O₂, respectively. Lane control: The starting materials. Lane labeling:
 483 FITC-labeled samples.



484


485 **Fig. S8.** Relative 8-oxoGua content in DNA and RNA of the VSMCs treated with or
 486 without H₂O₂, respectively, measured after FITC labeling. Statistical significance is
 487 indicated with * ($p \leq 0.05$) and ** ($p \leq 0.01$).

488



489

490 **Fig. S9.** ESI-ITMS characterization of the 12-nt DNA templates containing an 8-
 491 oxoGua, 8-oxoGua-N₃, 8-oxoGua-N₃-SS-Biotin, and 8-oxoGua-N₃-SH, respectively.
 492 The molecular weight is indicated with calculated value (m/z_{cal}) and observed value
 493 (m/z_{obs}), respectively.
 494




495

496 **Fig. S10.** ESI-ITMS characterization of the 10-nt RNA templates (without 8-oxoGua)
 497 undergoing APSC tagging reaction, click reaction with DBCO linker, and treatment
 498 with DTT. The molecular weight has not changed throughout the process. This result
 499 indicates the APSC adduct is not formed with the natural RNA without 8-oxoGua and
 500 the RNA chain is not degraded.

501


502



503

504 **Fig. S11.** Assessment for pull-down enrichment yield of the DNA and RNA templates,
505 respectively. Statistical significance is indicated with ** ($p \leq 0.01$) between DNA-8-
506 oxoGua and DNA-5-OHCyt as well as between RNA-8-oxoGua and RNA-5-OHUra,
507 respectively.

508




509

510 **Fig. S12.** Agarose gel electrophoresis analysis of PCR product. Lane a: 100-bp DNA
511 template. Lane b: 100-bp DNA containing 8-oxoGua-N3-SH. Lane c: PCR product
512 with Deep Vent® (exo-) DNA Polymerase (NEB). Lane d: PCR product with TruePrep
513 Amplify Enzyme (Vazyme). Lane e: PCR product with Pfu DNA Polymerase
514 (Promega). Lane f: PCR product with Q5® High-Fidelity DNA Polymerases (NEB).
515 Lane g: PCR product of the enriched sample using 8-oxoGua enrichment lacking APSC
516 labeling, under Deep Vent® (exo-) DNA Polymerase (NEB). No PCR product
517 indicated almost no nonspecific enrichment of DNA.


518

519



520


521 **Fig. S13.** Next-generation sequencing tests for enrichment of the DNA with 8-oxoGua
522 (DNA-8-oxoGua) than the DNA without 8-oxoGua (DNA-G) that were spiked in
523 genomic DNA fragments.



524

525 **Fig. S14.** qPCR verification for enrichment of the spiked DNA with or without (w/o)
526 an 8-oxoGua.


527



528

529 **Fig. S15.** qPCR verification for enrichment of the spiked 8-oxoGua-containing RNA.



530



531

532 **Fig. S16.** The results of APSC-8-oxoGua-seq for miRNAs of the VSMCs without H₂O₂
 533 treatment. The red dot indicated the typical miRNAs with 8-oxoGua modification in
 534 seed region.



535



536

537 **Fig. S17.** GO analysis (A) and KEGG analysis (B) for the differential target genes after
 538 substituting 8-oxoGua with U at position 2 of miR-1268a sequence.

539



540

541 **Fig. S18.** GO analysis (A) and KEGG analysis (B) of the differential target genes after
 542 substituting 8-oxoGua with U at position 8 of miR-1268a sequence.

543

Table S1. The overlapped oxidized miRNAs.

Name	Sequence (5'-3')
pal-miR-9993a-3p	ATCTCGGTGGGACCTCCA
hsa-miR-3168_R+1_1ss14AC	GAGTTCTACAGTCCGACA
hsa-miR-320d_R-1	AAAAGCTGGGTTGAGAGG
bta-miR-2478_L-2	ATCCCACTTCTGACACCA
hsa-miR-320a-3p	AAAAGCTGGGTTGAGAGGGCGA
hsa-miR-139-5p	TCTACAGTGCACGTGTCTCCAGT
hsa-miR-320b_R-2	AAAAGCTGGGTTGAGAGGGC
hsa-miR-3620-5p_R-2	GTGGGCTGGGCTGGGCTGGG
mmu-miR-3968_L-3_1ss14AT	ATCCCACTCCTGACACCA
cgr-mir-1285-p3_1ss1TC	CACTGCACTCCAGCCTGGGC
oan-miR-1386	CTCCTGGCTGGCTCGCCA
hsa-miR-92b-5p_R+2	AGGGACGGGACGCGGTGCAGTGTT
pal-miR-9226-5p_L-3	AGTCCCTGTTCGGGCGCCA
eca-miR-296_L-1R-3_1ss10GT	AGGGTTGGTTGGAGGCTT
pal-miR-9993b-3p_1ss9GT	ATCTCGCTTGGGCCTCCA
hsa-miR-1275_R+1	GTGGGGGAGAGGCTGTCTG
PC-3p-31279_64	AGCAGGACTGTGGCCATGGAAGT
hsa-mir-1303-p5	CTGGGCAACATAGCGAGAC
hsa-miR-486-5p	TCCTGTACTGAGCTGCCCCGAG
hsa-miR-125a-5p	TCCCTGAGACCCTTTAACCTGTGA
hsa-miR-320c_R-1	AAAAGCTGGGTTGAGAGGG
hsa-miR-483-5p_L-1R+3	AGACGGGAGGAAAGAAGGGAGTGG
hsa-miR-4484_L+2R-4	AAAAAAGGCGGGAGAAGC
hsa-miR-23a-5p	GGGGTTCCTGGGGATGGGATTT
hsa-miR-375-3p	TTGTTCGTTCGGCTCGCGTGA
eca-miR-296_L-1R-2	AGGGTTGGGTGGAGGCTTT
pal-miR-9993b-3p	ATCTCGCTGGGGCCTCCA
oan-miR-1386_1ss7GA	CTCCTGACTGGCTCGCCA
hsa-miR-574-5p	TGAGTGTGTGTGTGTGAGTGTGT
hsa-miR-122-5p_R-1	TGGAGTGTGACAATGGTGTTT
hsa-mir-5100-p3_1ss17TC	ATCCCAGCGGTGCCTCCA
mmu-mir-6240-p3_1ss22GT_1	ATTTCTGCCAGTGCTCTGAATG
efu-mir-9277-p5_1ss1CG	GGTGGCCGAGTGGTTAAG

hsa-miR-150-5p	TCTCCCAACCCTTGTACCAGTG
hsa-miR-99a-5p_R-1	AACCCGTAGATCCGATCTTGT
hsa-let-7c-5p	TGAGGTAGTAGGTTGTATGGTT
PC-3p-14138_148	AAAAGGGGGCTGAGGTGGAGG
hsa-miR-1268a	CGGGCGTGGTGGTGGGGG
hsa-miR-126-3p	TCGTACCGTGAGTAATAATGCG
hsa-miR-205-5p	TCCTTCATTCCACCGGAGTCTG
hsa-miR-145-5p	GTCCAGTTTTCCCAGGAATCCCT
hsa-miR-143-3p_R+1	TGAGATGAAGCACTGTAGCTCT
hsa-miR-203a-3p	GTGAAATGTTTAGGACCACTAG
hsa-miR-126-5p	CATTATTACTTTTGGTACGCG
mmu-mir-1983-p3_1ss2GA	TAATGCCGAGGTTGTGAGTT

545

546 **Table S2.** APSC-8-oxoGua-seq result of a 100-bp DNA template containing two 8-
547 oxoGua modification.

Position-base ^[a]	A ^[b]	C ^[b]	G ^[b]	T ^[b]
1C	0	30	0	0
2C	0	29	1	0
3G	0	0	30	0
4C	0	30	0	0
5T	0	0	0	30
6C	0	30	0	0
7G	0	0	30	0
8A	30	0	0	0
9G	0	0	30	0
10A	30	0	0	0
11T	0	0	0	30
12C	0	30	0	0
13G	0	0	30	0
14A	30	0	0	0
15T	0	0	0	30
16C	0	30	0	0
17G	0	0	30	0
18A	30	0	0	0
19T	0	0	0	30
20C	0	30	0	0
21G	0	0	30	0
22A	30	0	0	0
23T	0	0	0	30

24C	0	30	0	0
25G	0	0	30	0
26A	30	0	0	0
27T	0	0	0	30
28C	0	30	0	0
29G	0	0	30	0
30A	30	0	0	0
31A	30	0	0	0
32T	0	0	0	30
33C	0	30	0	0
8-oxoGua	0	0	3	27
35A	30	0	0	0
36T	0	0	0	30
37C	0	30	0	0
38G	0	0	30	0
39A	30	0	0	0
40T	0	0	0	30
41C	0	30	0	0
42G	0	0	30	0
43A	30	0	0	0
44T	0	0	0	30
45C	0	30	0	0
46G	0	0	30	0
47A	30	0	0	0
48T	0	0	0	30
49C	0	30	0	0
50G	0	0	30	0
51A	30	0	0	0
52T	0	0	0	30
53C	0	30	0	0
54A	30	0	0	0
55T	0	0	0	30
56C	0	30	0	0
57G	0	0	30	0
58T	0	0	0	30
59A	30	0	0	0
60G	0	0	30	0
61C	0	30	0	0
62A	30	0	0	0
63T	0	0	0	30
64C	0	30	0	0
8-oxoGua	0	0	5	25
66A	30	0	0	0
67C	0	30	0	0

68A	30	0	0	0
69T	0	0	0	30
70G	0	0	30	0
71A	30	0	0	0
72T	0	0	0	30
73C	0	30	0	0
74G	0	0	30	0
75A	30	0	0	0
76T	0	0	0	30
77C	0	30	0	0
78G	0	0	30	0
79A	30	0	0	0
80A	30	0	0	0
81T	0	0	0	30
82C	0	30	0	0
83G	0	0	30	0
84A	30	0	0	0
85T	0	0	0	30
86C	0	30	0	0
87G	0	0	30	0
88A	30	0	0	0
89T	0	0	0	30
90C	0	29	0	1
91G	0	0	30	0
92A	29	0	1	0
93G	0	0	30	0
94G	0	0	30	0
95T	0	0	0	30
96A	30	0	0	0
97C	0	30	0	0
98C	0	30	0	0
99C	0	30	0	0
100A	30	0	0	0

548 [a] Position and pre-designed base type in positive-sense strand of DNA from 5' to 3'.

549 [b] The number of base (namely A, C, G, T) in sequencing reads at each position.

550

551 References

- 552 1. M. E. Hosford, J. G. Muller and C. J. Burrows, *Journal of the American Chemical Society*, 2004,
553 **126**, 9540-9541.
- 554 2. L. Xue and M. M. Greenberg, *Journal of the American Chemical Society*, 2007, **129**, 7010-+.
- 555 3. J. X. Wang, J. Gao, S. L. Ding, K. Wang, J. Q. Jiao, Y. Wang, T. Sun, L. Y. Zhou, B. Long, X. J. Zhang,

556 Q. Li, J. P. Liu, C. Feng, J. Liu, Y. Gong, Z. Zhou and P. F. Li, *Mol Cell*, 2015, **59**, 50-61.
557 4. C. X. Song, K. E. Szulwach, Y. Fu, Q. Dai, C. Yi, X. Li, Y. Li, C. H. Chen, W. Zhang, X. Jian, J. Wang, L.
558 Zhang, T. J. Looney, B. Zhang, L. A. Godley, L. M. Hicks, B. T. Lahn, P. Jin and C. He, *Nat*
559 *Biotechnol*, 2011, **29**, 68-72.
560
561
562
563